Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of ponsegromab in cancer cachexia
2022-003016-87Phase 2Active
- Sponsor
- Pfizer
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer anorexia-cachexia syndrome (CACS) comparing Ponsegromab with Placebo (2 arms). Primary endpoint: Change from baseline body weight at Week 12. Started Nov 2022; status: active.
02
Drugs
ponsegromab
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on 2022-003016-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003016-87.